Related Experiment Video
Updated: May 24, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
Dynamic regulation-based stabilizing mutations are highly effective for designing RSV pre-fusion F mRNA vaccines
Shuai Shao1, Ze Yuan Dong2, Zi Yao Kang3
1The Sixth Laboratory, National Vaccine and Serum Institute (NVSI), Beijing, 101111, China; National Engineering Center for New Vaccine Research, Beijing, 101111, China.
Abstract:
Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections and poses a serious threat to young children, older adults, and immunocompromised individuals. We previously designed a pre-fusion stabilized F protein (pre-F), TriM-5, using a dynamic regulation mechanism, and produced a recombinant protein-based vaccine candidate that exhibited potent protection against RSV. However, several studies have revealed that the stabilization of pre-F achieved in protein form may not be sufficient for application in mRNA vaccine development. Here, based on TriM-5, we designed an mRNA vaccine candidate to assess whether the dynamic regulation-based stabilizing mutations of TriM-5 are also effective in an mRNA format. The TriM-5 mRNA was codon-optimized using in-house software named NVSI_GAmRNAopt, which employed a genetic algorithm incorporating multiple empirical parameters for coding sequence (CDS) optimization, and encapsulated using lipid nanoparticles (LNPs). Mouse immunization showed that after CDS optimization, the IgG antibody titers increased approximately threefold, indicating the effectiveness of our codon-optimization algorithm. Compared with the Moderna RSV mRNA sequence encapsulated with our proprietary BM028 LNPs, the TriM-5 mRNA-LNP induced 3.03-fold higher neutralizing antibody titers against RSV A2 virus, along with significantly higher IFN-γ, IL-5 and IL-17A secretion levels, indicating its superior immunogenicity. Virus challenge experiments demonstrated that both TriM-5 mRNA-LNP and Moderna mRNA-LNP reduced lung viral loads effectively, with no obvious lung pathology. The designed TriM-5 mRNA-LNP exhibits good immunogenicity and protective efficacy, and thereby may serve as a promising candidate for further vaccine development.
Insights
A novel messenger RNA (mRNA) vaccine candidate targeting respiratory syncytial virus (RSV) demonstrated superior immunogenicity and protection in mice. This RSV mRNA vaccine, based on a stabilized F protein, shows promise for future vaccine development.
Area of Science:
- Vaccinology
- Virology
- Molecular Biology
Background:
- Respiratory syncytial virus (RSV) causes severe respiratory infections, particularly in vulnerable populations.
- Existing protein-based RSV vaccines may have limitations for mRNA vaccine development.
- Stabilized pre-fusion F protein (pre-F) strategies are crucial for effective RSV vaccine design.
Purpose of the Study:
- To develop and evaluate an mRNA vaccine candidate based on the pre-fusion stabilized F protein, TriM-5.
- To assess the efficacy of dynamic regulation-based stabilizing mutations in an mRNA vaccine format.
- To optimize the mRNA coding sequence (CDS) for enhanced immunogenicity.
Main Methods:
- Designed a TriM-5 mRNA vaccine candidate with codon optimization using NVSI_GAmRNAopt software.
- Encapsulated the mRNA using lipid nanoparticles (LNPs).
- Performed mouse immunization studies, including antibody titer measurements, cytokine analysis, and virus challenge experiments.
Main Results:
- Codon optimization of the mRNA CDS increased IgG antibody titers approximately threefold.
- The TriM-5 mRNA-LNP induced 3.03-fold higher neutralizing antibody titers compared to a Moderna RSV mRNA sequence.
- Both TriM-5 mRNA-LNP and Moderna mRNA-LNP effectively reduced lung viral loads with no significant lung pathology.
Conclusions:
- The TriM-5 mRNA-LNP vaccine candidate demonstrates superior immunogenicity and protective efficacy against RSV in a mouse model.
- The codon optimization algorithm and stabilizing mutations are effective in the mRNA vaccine format.
- This TriM-5 mRNA-LNP holds significant potential for future RSV vaccine development.
Related Concept Videos
Translational Regulation
RNA Stability
Leaky Scanning
Regulation of Expression at Multiple Steps
Viral Mutations

